What Acadia Investors Need to Know About This Stock's Pop Today

Shares of ACADIA Pharmaceuticals (NASDAQ: ACAD  ) shot through the roof today, up 30% as of this filming. In the video below, Fool health-care analyst David Williamson discusses news of some great phase 3 trial results for the company's drug Pimavanserin, which treats psychosis in patients with Parkinson's disease. David tells investors how good the results were, and what advantages this drug candidate could have over its competition if it reaches FDA approval.

Is Eli Lilly a buy or sell?
With two of its top three drugs poised to lose patent protection this year, is Eli Lilly a dividend stock headed nowhere fast? In a new premium report, The Motley Fool's senior pharmaceuticals analyst breaks down all of Lilly's moving parts, including an in-depth analysis of the company's must-know opportunities, and reasons to buy and sell today. To find out more click here to claim your copy today.


Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On March 21, 2013, at 7:47 PM, TimKnows wrote:

    This stock is making me millions, its been a few years but its been worth it.

Add your comment.

DocumentId: 2326177, ~/Articles/ArticleHandler.aspx, 4/20/2014 1:49:48 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement